126-BB:1 Definitions. – In this chapter: I. 'Board' means the New Hampshire prescription drug affordability board. II. 'Brand-name drug' means a prescription drug marketed under a proprietary name or registered trademark name, including a biological product. III. 'Generic drug' means a prescription drug, whether identified by its chemical, proprietary, or nonproprietary name, that is not a brand-name drug and is therapeutically equivalent to a brand-name drug in dosage, safety, strength, method of consumption, quality, performance, and intended use. 'Generic drug' includes a biosimilar product. IV. 'Manufacturer' means a manufacturer of prescription drugs that are distributed in the state. A manufacturer excludes a packager, repackager, labeler, and relabeler unless the packager, repackager, labeler, or relabeler sets the price or controls the price of a prescription drug. V. 'Pricing unit' means the smallest available package that can be used to dispense the smallest amount of a prescription drug. VI. 'Public payor' means any division of state, county, or municipal government that administers a health plan for its employees or an association of state, county, or municipal a prescription drug. VI. 'Public payor' means any division of state, county, or municipal government that administers a health plan for its employees or an association of state, county, or municipal employers that administers a health plan for its employees. VII. 'Wholesale acquisition cost' means a manufacturer's listed price for sale to a wholesale drug distributor or other entity that purchases a prescription drug directly from the manufacturer, not including any price concessions. Source. 2020, 13:5, eff. July 1, 2020. 2022, 244:1, eff. July 1, 2022.
New Hampshire Legal Code